[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345316-105":59,"doc-detail-345316-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","increased-prevalence-of-extrathymic-neoplasms-in-myasthenia-gravis-patients-a-population-based-matched-case-control-study","Increased Prevalence of Extrathymic Neoplasms in Myasthenia Gravis Patients - A Population-Based, Matched Case–Control Study","","This population-based matched case–control study evaluates malignancy rates in myasthenia gravis (MG) patients while accounting for disease characteristics and immunomodulatory treatments. Using the Clalit Health Services database, the study applies a machine learning algorithm to reduce diagnosis misclassification and compares prevalence and hazard ratios of extrathymic neoplasms between matched groups. MG is associated with higher pre- and post-diagnosis malignancy risks, with age, male sex, and thymoma as key factors. Immunosuppressive therapy does not increase risk.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/increased-prevalence-of-extrathymic-neoplasms-in-myasthenia-gravis-patients-a-population-based-matched-case-control-study/345316/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/increased-prevalence-of-extrathymic-neoplasms-in-myasthenia-gravis-patients-a-population-based-matched-case-control-study/345316.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was the MG study population identified and classified?","Question",{"text":112,"@type":113},"MG patients were selected from the Clalit Health Services database and diagnosis misclassification was minimized using a machine learning algorithm.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did the study find about malignancy risk before and after MG diagnosis?",{"text":117,"@type":113},"MG patients showed a higher prevalence of malignancy before MG diagnosis and a higher incidence after diagnosis, with odds and hazard ratios reported in the results.",{"name":119,"@type":110,"acceptedAnswer":120},"Which risk factors were associated with malignancy in MG patients?",{"text":121,"@type":113},"Risk factors included age, male sex, and thymoma, while immunosuppressive treatment did not increase malignancy risk.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345316,1790648984,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Muscle & Nerve  \nCLINICAL RESEARCH ARTICLE  OPEN ACCESS   \nIncreased Prevalence of Extrathymic Neoplasms in Myasthenia Gravis Patients-A Population-Based, Matched Case–Control Study  \nKeshet Pardo1,2  | Tasneem Kab1 | Mark A. Hellmann1,2 | Itay Lotan1,2  | Tzippy Shochat3 | Nadav Loebl4,5 | Bar Yacobi4 | Yitzhak Friedman1,2 | Leor Perl2,4,6 | Nitai Shimon7 | Yiska Loewenberg Weisband8 | Liya Bieber8 | Eitan Auriel1,2  | Adi Wilf-Yarkoni1,2   \n1Department of Neurology, Rabin Medical Center, Petach Tikva, Israel | 2Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel | 3Statistical Consultant, Rabin Medical Center, Petach Tikva, Israel | 4Beilinson Medical Center Innovation, Artificial Intelligence Center, Rabin Medical Center, Petah Tikva, Israel | 5Faculty of Computer Science, Reichman University, Herzliya, Israel | 6Department of Cardiology, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel | 7Departmet of Neurology, Shamir Medical Center, Beer Yaakov, Israel | 8Clalit Health Services, Clalit Research Institute, Tel Aviv, Israel  \nCorrespondence: Adi Wilf-Yarkoni ([adi.wilf@gmail.com](adi.wilf@gmail.com))  \nReceived: 26 June 2025 | Revised: 24 February 2026 | Accepted: 27 February 2026  \nKeywords: artificial intelligence | extra-thymic malignancy | machine learning | malignancy | myasthenia gravis  \nABSTRACT  \nIntroduction/Aims: Myasthenia gravis (MG) is associated with thymic neoplasms. However, an increased prevalence of extrathymic neoplasms has also been reported. This study aimed to evaluate the rates of malignancy in MG patients while accounting for risk factors such as disease characteristics and immunomodulatory treatments.  \nMethods: We conducted a case–control study using the Clalit Health Services database, applying a machine learning (ML) algorithm to minimize diagnosis misclassification. We included MG patients aged 18 years and older, with a sex-and age-matched control group in a 1:3 ratio. We compared the prevalence and hazard ratios of extrathymic neoplasms between the groups. Results: A total of 1558 patients with a high probability of MG, according to our ML model, were included in the cohort, alongside a control group of 4674 individuals. MG patients had a higher prevalence of malignancy prior to MG diagnosis, with an odds ratio of 1.95 (95% CI, 1.65–2.08), and a higher incidence of malignancy after MG diagnosis, with a hazard ratio of 1.56 (95% CI, 1.38–1.77). The most prevalent extrathymic neoplasms after MG diagnosis were respiratory, intrathoracic, skin (specifically nonmelanoma), urinary tract, soft tissue, and myelodysplastic syndrome. Risk factors for malignancy included age, male sex, and thymoma. Immunosuppressive treatment did not increase the risk of malignancy.  \nDiscussion: MG patients have a higher prevalence of both solid and hematologic neoplasms compared to non-myasthenic controls, regardless of immunosuppressive treatment. This supports the notion that malignancy is related to MG disease itself rather than external factors.  \n1 | Introduction  \nMyasthenia gravis (MG) is associated with thymoma in 10%– 15% of patients, and 30%–50% of those with thymoma develop MG [1, 2]. Thymoma is not the only malignancy associated with  \nMG. Numerous reports have suggested a higher prevalence of malignancies in MG patients and an increased incidence following an MG diagnosis [3, 4] . However, there is inconsistency regarding which malignancies may be associated with MG. Some studies have reported associations with skin cancers [5], male  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2026 The Author(s). Muscle & Nerve published by Wiley Periodicals LLC.  \n1016 Muscle & Nerve, 2026; 73:1016–1024  \n[https://doi.org/10.1002/mus.70207](https://doi.org/10.1002/mus.70207)  \nand fe","cbCairCt9RCSbbR5","https://ap.wps.com/l/cbCairCt9RCSbbR5","pdf",1573764,"English","# Introduction\n## Background and prior evidence\n## Study aim\n# Methods\n## Study design and data collection","[{\"question\":\"How was the MG study population identified and classified?\",\"answer\":\"MG patients were selected from the Clalit Health Services database and diagnosis misclassification was minimized using a machine learning algorithm.\"},{\"question\":\"What did the study find about malignancy risk before and after MG diagnosis?\",\"answer\":\"MG patients showed a higher prevalence of malignancy before MG diagnosis and a higher incidence after diagnosis, with odds and hazard ratios reported in the results.\"},{\"question\":\"Which risk factors were associated with malignancy in MG patients?\",\"answer\":\"Risk factors included age, male sex, and thymoma, while immunosuppressive treatment did not increase malignancy risk.\"}]","Increased Prevalence of Extrathymic Neoplasms in Myasthenia Gravis Patients - A Population-Based, Matched Case–Control Study | PDF",1790057243,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8aa56d16530235ea79f312a12530b3c2.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c7cb300ac7337d988f5b72d14c525d9f.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4997ca670203a3bad5874cd931975842.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac7301020a36877242e3423fcd75b6f0.webp",980,1287]